J&J’s Janssen taps into Pipeline Therapeutics’ neuroscience asset for $50M upfront
Johnson & Johnson’s Janssen unit is delving into the muscarinic space with $50 million upfront for an oral Pipeline Therapeutics asset that will enter a Phase II in the second half of this year, CEO and president Carmine Stengone told Endpoints News.
The San Diego biotech tested its investigational compound, the muscarinic M1 antagonist PIPE-307, in two Phase I studies and has gained an FDA go-ahead for a mid-stage study in patients with relapsing-remitting multiple sclerosis, or RRMS. After the Phase I studies showed a “clean safety profile,” Pipeline attracted “a fair bit of partnering interest,” with a few term sheets negotiated during the process, Stengone said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
